CN114869949A - A pharmaceutical composition for treating puerperal diseases, and its preparation method - Google Patents

A pharmaceutical composition for treating puerperal diseases, and its preparation method Download PDF

Info

Publication number
CN114869949A
CN114869949A CN202210587997.XA CN202210587997A CN114869949A CN 114869949 A CN114869949 A CN 114869949A CN 202210587997 A CN202210587997 A CN 202210587997A CN 114869949 A CN114869949 A CN 114869949A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
traditional chinese
prepared
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210587997.XA
Other languages
Chinese (zh)
Other versions
CN114869949B (en
Inventor
杨履中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANXI YELLOW RIVER TRADITIONAL CHINESE MEDICINE CO Ltd
Original Assignee
SHANXI YELLOW RIVER TRADITIONAL CHINESE MEDICINE CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANXI YELLOW RIVER TRADITIONAL CHINESE MEDICINE CO Ltd filed Critical SHANXI YELLOW RIVER TRADITIONAL CHINESE MEDICINE CO Ltd
Priority to CN202210587997.XA priority Critical patent/CN114869949B/en
Publication of CN114869949A publication Critical patent/CN114869949A/en
Application granted granted Critical
Publication of CN114869949B publication Critical patent/CN114869949B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/58Reptiles
    • A61K35/586Turtles; Tortoises, e.g. terrapins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/618Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/344Codonopsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/46Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating postpartum diseases of women, which is prepared from the following traditional Chinese medicines or traditional Chinese medicine extracts in parts by weight: 8-16 parts of radix astragali preparata, 8-16 parts of codonopsis pilosula, 8-16 parts of eucommia ulmoides charcoal, 8-16 parts of wine-processed scutellaria baicalensis, 16-24 parts of prepared rehmannia root, 16-24 parts of teasel root, 8-16 parts of soil-fried bighead atractylodes rhizome, 8-16 parts of vinegar-processed turtle shell, 20-30 parts of calcined oyster shell, 5-10 parts of Chinese date and 3-6 parts of pseudo-ginseng. The medicine composition for treating the postpartum diseases of women and the preparation method thereof have the effects of tonifying qi and blood, promoting blood circulation to relieve pain, tonifying liver and kidney, nourishing yin to clear heat, stopping bleeding and stopping sweating.

Description

A pharmaceutical composition for treating puerperal diseases, and its preparation method
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating postpartum diseases of women and a preparation method thereof.
Background
Postpartum diseases, also known as puerperal diseases, refer to diseases related to childbirth or puerperium of pregnant women during the puerperium period after childbirth (including small childbirth). The puerpera needs 6-8 weeks after the parturient produces the baby to recover the body to the normal state, and the period is called the puerperium, namely the folk so-called sitting moon. Postpartum diseases may be caused by blood loss and body fluid loss, blood stasis and internal resistance, primordial qi damage, viscera injury, void of hundred joints, weak striae, weak defensive exterior and inadequate nursing. The common puerperal diseases include uterine hypoplasia, puerperal hemorrhage, puerperal fever, puerperal night sweat, puerperal infection, puerperal headache, body pain, puerperal arthralgia, puerperal pollakisuria, urinary incontinence, puerperal galactorrhea, acute mastitis, hypogalactia, puerperal depression, etc. The diseases not only seriously affect the physical and mental health of the lying-in women, but also prevent the lying-in women from nursing normally. Therefore, the medicine should realize early prevention, early discovery and early treatment of postpartum diseases, and has very important significance for ensuring the health of puerperae and neonate.
The traditional Chinese medicine has a long history of treating postpartum diseases, the traditional Chinese medicine considers that the postpartum diseases are diseases with deficiency or excess and abundant deficiency, and the diseases related to delivery and puerperium occurring from the delivery of a fetus to the puerperium are called postpartum diseases. That is, the deficiency of both qi and blood in traditional Chinese medicine. Qi is yang and blood is yin, so in Duan Jing twenty two difficult, it says that qi governs warm and blood governs soft-heat. However, there are close relations between qi and blood, that is, qi is the commander of blood and blood is the mother of qi.
The traditional Chinese medicine considers that the etiology and pathogenesis of various postpartum diseases are four points:
bleeding and body fluid loss:
when the yin-blood suddenly dies due to labor, sweating, wound and bleeding during childbirth, the deficient yang floats, i.e., the blood is deficient. Excessive blood loss and insufficient generation and supplement of new blood, and blood deficiency caused by hypofunction or insufficient source of blood generation due to weakness of spleen and stomach and insufficient nutrition in diet, blood liquefaction and generation disorder can cause blood deficiency, so that lusterless complexion, pale and lusterless nails, dizziness, palpitation, listlessness, emaciation, dry eyes, blurred vision and the like can occur. Susceptible to postpartum anemic fainting, postpartum convulsion, postpartum fever, postpartum constipation, postpartum stranguria and postpartum blood strain.
Second, the original qi is damaged:
parturition is a prolonged and continuous process of physical exertion. If the labor is too long, the labor is too much and the qi is consumed too early during the labor, and the qi is consumed along with the blood, which may cause obstruction of urination, lochiorrhea, galactorrhea, sweating, fever and blood fatigue after delivery.
③ blood stasis and internal resistance:
blood stasis is mainly caused by unsmooth blood flow. Obstructed qi flow can cause stasis. Wound during childbirth, damaged meridians, blood overflowing from the vessels and transforming into stasis. After delivery, all the joints are empty and qi deficiency fails to promote blood circulation, which can cause stasis. If the patient cares carelessly in daily life, the patient feels the pathogenic cold and heat, and the congealing cold and heat can cause stasis; or residual placenta and placenta, and blood stasis, which can cause puerperal abdominal pain, puerperal fever, puerperal lochiorrhea, and puerperal depression.
Fourthly, the external infection is caused by six excesses or the food and the sexual overstrain:
the excessive qi and body fluids of postpartum can cause the diseases of qi and blood disorder, malnutrition, dysfunction of zang-fu organs and thoroughfare and conception vessel damage after birth, because the skin and skin striae are loosened due to the deficiency of the space between joints and muscles of postpartum, which can lead to the diseases after birth caused by careless life or improper regulation.
In short, postpartum diseases are mainly "deficiency" and "stasis", so there is a saying "postpartum excessive deficiency and stasis", and sometimes the deficiency and stasis are mixed. The pathogenesis of 'deficiency and stasis' formed by postpartum blood loss and body fluid loss, original qi damage and blood stasis internal resistance is the basis and internal cause of postpartum diseases.
At present, the traditional Chinese medicine has definite curative effect, safety, little side effect and little stimulation and damage to gastrointestinal tracts when being used for treating postpartum diseases, and is clinically proven. The treatment of postpartum diseases should be based on the characteristics of fluid loss due to blood consumption, internal obstruction of blood stasis, and excessive deficiency and stasis, and should be used for regulating qi and blood regardless of deficiency or excess. Based on the principle of "not being restricted to postpartum nor forgetting to postpartum", syndrome differentiation and treatment are performed in combination with the disease condition. The book Jingyue quan Shu says: all qi and blood after delivery are removed, the excessive disharmony is true, the deficient syndrome is natural, the deficient syndrome is not true, the full excess is true, all the three are treated by the conventional method when the deficiency and excess are distinguished according to the syndrome, and the disharmony is true without reinforcing the whole body, so as to help evil. "postpartum excessive deficiency should be mainly due to great qi and blood tonification, but its administration should prevent stagnation and help evil; postpartum excessive blood stasis is treated by the method of activating blood and resolving stasis, and then blood-nourishing is added to activate blood and resolve stasis, so as to eliminate pathogens without damaging healthy qi and resolve stasis without damaging blood. When the prescription is selected, qi and blood must be treated. The Chinese medicinal composition can relieve depression without excessive dissipation, eliminate stagnation, strengthen spleen, dispel cold without excessive dryness, clear heat without excessive bitter cold. Meanwhile, the postpartum medication should be controlled. The third ban, namely forbidding the profuse sweating to prevent yang exhaustion; forbidding drastic purgation to prevent yin depletion; to prevent the loss of body fluids, the urination is prohibited.
For postpartum diseases, the prescription should be taken with qi and blood, qi circulation is not too much dissipated, digestion and guidance should support spleen, cold syndrome should not be used excessively to warm and dry, heat syndrome should not be used excessively to cool and cool, so that tonification can not be stagnated, and diarrhea can not be injured.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating postpartum diseases of women and a preparation method thereof, and the pharmaceutical composition has the effects of tonifying qi and blood, promoting blood circulation, relieving pain, tonifying liver and kidney, nourishing yin, clearing heat, stopping bleeding and arresting sweating.
In order to achieve the purpose, the invention provides a pharmaceutical composition for treating postpartum diseases of women, which is prepared from the following traditional Chinese medicines or traditional Chinese medicine extracts in parts by weight: 8-16 parts of radix astragali preparata, 8-16 parts of codonopsis pilosula, 8-16 parts of eucommia ulmoides charcoal, 8-16 parts of wine-processed scutellaria baicalensis, 16-24 parts of prepared rehmannia root, 16-24 parts of teasel root, 8-16 parts of soil-fried bighead atractylodes rhizome, 8-16 parts of vinegar-processed turtle shell, 20-30 parts of calcined oyster shell, 5-10 parts of Chinese date and 3-6 parts of pseudo-ginseng.
Preferably, the pharmaceutical composition is prepared from the following traditional Chinese medicines in parts by weight: 8 parts of radix astragali preparata, 9 parts of codonopsis pilosula, 12 parts of charred eucommia ulmoides, 10 parts of wine-processed scutellaria baicalensis, 18 parts of prepared rehmannia root, 16 parts of teasel root, 12 parts of soil-fried bighead atractylodes rhizome, 10 parts of vinegar turtle shell, 28 parts of calcined oyster shell, 10 parts of Chinese date and 4 parts of pseudo-ginseng.
Preferably, the pharmaceutical composition is prepared from the following traditional Chinese medicines in parts by weight: 15 parts of radix astragali preparata, 12 parts of codonopsis pilosula, 14 parts of charred eucommia ulmoides, 15 parts of wine-processed scutellaria baicalensis, 16 parts of prepared rehmannia root, 24 parts of teasel root, 8 parts of soil-fried bighead atractylodes rhizome, 8 parts of vinegar turtle shell, 22 parts of calcined oyster shell, 6 parts of Chinese date and 5 parts of pseudo-ginseng.
Preferably, the pharmaceutical composition is prepared from the following traditional Chinese medicines in parts by weight: 15 parts of radix astragali preparata, 10 parts of codonopsis pilosula, 10 parts of charred eucommia ulmoides, 6 parts of wine-processed scutellaria baicalensis, 10 parts of prepared rehmannia root, 10 parts of teasel root, 8 parts of soil-fried bighead atractylodes rhizome, 12 parts of vinegar turtle shell, 20 parts of calcined oyster shell, 5 parts of Chinese date and 3 parts of pseudo-ginseng.
Preferably, the composition also comprises pharmaceutically acceptable auxiliary materials.
Preferably, the pharmaceutical composition is any one of pharmaceutical oral preparations, and the oral preparation is granules, tablets, capsules, powder or pills.
A preparation method of a pharmaceutical composition for treating postpartum diseases of women comprises the following steps:
s1, extracting the traditional Chinese medicine raw materials in parts by weight with water for 2-4 times according to the proportion, adding 10-15 times of water each time, and decocting for 0.5-2 hours;
s2, filtering and combining the filtrates obtained in the step S1, concentrating the filtrates to an extract with the relative density of 1.00-1.50, drying and crushing to obtain the tea extract.
Therefore, the pharmaceutical composition for treating the postpartum diseases of the women and the preparation method thereof have the effects of tonifying qi and blood, promoting blood circulation to relieve pain, tonifying liver and kidney, nourishing yin to clear heat, stopping bleeding and arresting sweating. Can be used for treating puerperal deficiency of both qi and yin, heat disturbance of thoroughfare and conception vessels, and internal resistance due to blood stasis, manifested by lusterless complexion, dizziness, asthenia, soreness of waist and knees, vexation, dry mouth, lower abdominal pain, little or no lochiorrhea, sweating, constipation due to qi deficiency, chronic ulcer, and puerperal blood diseases.
The astragalus root in the medicine composition is good at tonifying qi, especially good at invigorating yang, and qi and feet can promote blood circulation, so that the medicine composition can tonify both qi and blood, and is a monarch medicine. The rhizoma atractylodis macrocephalae fried with soil is used for tonifying spleen and qi, and is combined with the radix astragali to enhance the effect of tonifying qi; radix Codonopsis tonifies spleen and lung qi, strengthens body resistance and eliminates pathogenic factors; blood deficiency can cause malnutrition of heart and liver, prepared rehmannia root is sweet and warm and moist, has the effects of enriching blood and nourishing yin, replenishing essence and benefiting marrow, prepared rehmannia root is dominant and static in nature and belongs to yin, radix codonopsitis and soil-fried bighead atractylodes rhizome are dominant and belongs to yang, the three medicines are combined with astragalus root, the qi and blood are supplemented, the yin and yang are considered, and the movement are combined. Sufficient qi can generate and circulate blood, sufficient blood can assist qi and qi, and the qi are complementary and are used as ministerial drugs.
The wine-processed radix Scutellariae relieves the cold and cool nature and clears the heat in the upper-jiao. The charred eucommia bark can tonify liver and kidney, strengthen tendons and bones. Stir-baked Chuan Fang Ji, tonifying liver and kidney, strengthening tendons and bones, and treating metrorrhagia and metrostaxis. Vinegar carapax Trionycis has effects of nourishing yin, suppressing yang, relieving fever, and removing steaming. Calcined mu Li can suppress yang and tonify yin, astringe and astringe. Notoginseng radix has effects of stopping bleeding, retaining blood stasis, removing blood stasis and not damaging healthy qi. Assistant monarch and minister drugs, strengthen the body resistance and tonify deficiency, nourish yin and suppress yang, activate blood and stop bleeding, remove steam and stop sweating.
The Chinese date is used as a guiding drug and added with the harmonizing drugs as a guiding drug. The medicines are matched to play the roles of tonifying qi and blood, tonifying liver and kidney, strengthening muscles and bones, removing blood stasis and arresting sweating, so that qi and blood are sufficient, qi in spleen and stomach is generated, yin and yang are balanced, and the body function is recovered quickly.
The technical solution of the present invention is further described in detail by the following examples.
Detailed Description
The technical solution of the present invention is further illustrated by the following examples.
Unless defined otherwise, technical or scientific terms used herein shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art. These other embodiments are also covered by the scope of the present invention.
It should be understood that the above-mentioned embodiments are only for explaining the present invention, and the protection scope of the present invention is not limited thereto, and any person skilled in the art should be able to cover the technical scope of the present invention and the equivalent replacement or change of the technical solution and the inventive concept thereof in the technical scope of the present invention.
The specific meanings of the above terms in the present invention can be understood by those skilled in the art according to specific situations. The term "about" as used herein has the meaning well known to those skilled in the art, and preferably means that the term modifies a value within the range of ± 50%, ± 40%, ± 30%, ± 20%, ± 10%, ± 5% or ± 1% thereof.
All terms (including technical or scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs unless specifically defined otherwise. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
Techniques, methods, and apparatus known to those of ordinary skill in the relevant art may not be discussed in detail but are intended to be part of the specification where appropriate.
The disclosures of the prior art documents cited in the present description are incorporated by reference in their entirety and are therefore part of the present disclosure.
Example one
The pharmaceutical composition is prepared from the following traditional Chinese medicines in parts by weight: 8 parts of radix astragali preparata, 9 parts of codonopsis pilosula, 12 parts of charred eucommia ulmoides, 10 parts of wine-processed scutellaria baicalensis, 18 parts of prepared rehmannia root, 16 parts of teasel root, 12 parts of soil-fried bighead atractylodes rhizome, 10 parts of vinegar turtle shell, 28 parts of calcined oyster shell, 10 parts of Chinese date and 4 parts of pseudo-ginseng.
The components are weighed according to the parts by weight and then decocted for 3 times by adding water, the amount of water used for each time is 10 times of the mass of the traditional Chinese medicine mixture, and the decoction lasts for 1 hour. Mixing the filtrates, concentrating to obtain an extract with a relative density of 1.15-1.20 (room temperature), drying under reduced pressure, and pulverizing into fine powder. Granulating by wet method, and drying to obtain granule.
Example two
The pharmaceutical composition is prepared from the following traditional Chinese medicines in parts by weight: 15g of radix astragali Preparata, 10g of radix Codonopsis, 10g of charred eucommia bark, 6g of wine-processed Scutellaria baicalensis, 10g of prepared rehmannia root, 10g of teasel root, 8g of stir-fried Atractylodes macrocephala, 12g of vinegar turtle shell, 20g of calcined oyster shell, 5g of Chinese date and 3g of pseudo-ginseng.
A preparation method of a pharmaceutical composition for treating postpartum diseases of women comprises the following steps:
s1, extracting the traditional Chinese medicine raw materials in certain parts by weight with water for 3 times according to the proportion, adding 10 times of water each time, and decocting for 1 h;
s2, filtering and combining the filtrates obtained in the step S1, concentrating the filtrates to obtain an extract with the relative density of 1.15-1.20 (room temperature), drying and crushing the extract to obtain the Chinese medicinal composition.
EXAMPLE III
First, case analysis
100 postpartum patients with clinically confirmed diagnosis are randomly selected, one of the major symptoms and the minor symptoms is found in the clinical diagnosis standard, and the patients can be included in the analysis data when the conditions accord with the tongue pulse.
The main symptoms are: firstly, the postnatal lower abdomen is dull and painful, is easy to knead and press, has little lochia, light color, dizziness, palpitation, severe palpitation, constipation, pale red tongue, thin and white fur and thready and weak pulse. ② the postpartum retention of cold and hot, persistent lochia or little lochia, dark purple with lumps, pain and tenderness in the lower abdomen, dark purple tongue or ecchymosis in the ecchymosis, wiry, unsmooth and powerful pulse.
The secondary symptoms are as follows: firstly, soreness and weakness of waist and knees; ② weakness of limbs; ③ bad appetite; fourthly, aversion to wind and sweating.
Pulse of tongue: dark tongue with thin and white coating and deep and wiry or deep and slow pulse.
Second, Experimental methods
100 patients confirmed to take the powder prepared in example two 3 times a day in 1 bag each time, and 10g of the powder prepared in example two is contained in each bag. The condition of the patient under examination was followed after 2 weeks.
Wherein, the evaluation standard of the curative effect is as follows: firstly, curing: disappearance of clinical symptoms, effect development: the main symptoms are basically eliminated, the physical function is recovered, and the labor and the work can be participated; ③ effective: the major symptoms are reduced and require long conditioning times. Fourthly, invalidation: original symptoms and signs are not relieved.
As a result, 83 cases were cured (83%), 17 cases were effective (17% effective), and 0 cases were ineffective (0% ineffective).
Example four
20 postpartum KM mice were randomly divided into 2 groups, and the drug prepared in example two was gavaged 1 time a day by 4.55g/kg (equivalent to 1 time the clinical dose of normal persons) in the experimental group. The blank control group was infused with the same amount of physiological saline, the test group and the control group were sacrificed 7 days after the infusion, and the uterus condition was observed.
The uterine congestion area of pregnant mice in the test group is 1/3, uterine edema + and placenta attachment surface is smooth. The uterine congestion area of the pregnant mouse in the control group is 2/3, the degree of uterine edema is +++, and the placenta attachment surface is rough.
Therefore, the medicine composition for treating the postpartum diseases of the women and the preparation method thereof have the effects of tonifying qi and blood, promoting blood circulation to relieve pain, tonifying liver and kidney, nourishing yin to clear heat, stopping bleeding and arresting sweating, and are used for treating the symptoms of qi and yin deficiency, heat disturbance of thoroughfare and conception vessels, internal blood stasis and the like of the postpartum women.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting the same, and although the present invention is described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that: modifications and equivalents may be made to the invention without departing from the spirit and scope of the invention.

Claims (7)

1. The pharmaceutical composition for treating postpartum diseases of women is characterized by being prepared from the following traditional Chinese medicines or traditional Chinese medicine extracts in parts by weight: 8-16 parts of radix astragali preparata, 8-16 parts of codonopsis pilosula, 8-16 parts of eucommia ulmoides charcoal, 8-16 parts of wine-processed scutellaria baicalensis, 16-24 parts of prepared rehmannia root, 16-24 parts of teasel root, 8-16 parts of soil-fried bighead atractylodes rhizome, 8-16 parts of vinegar-processed turtle shell, 20-30 parts of calcined oyster shell, 5-10 parts of Chinese date and 3-6 parts of pseudo-ginseng.
2. The pharmaceutical composition for treating postpartum diseases of women according to claim 1, which is prepared from the following traditional Chinese medicines in parts by weight: 8 parts of radix astragali preparata, 9 parts of codonopsis pilosula, 12 parts of charred eucommia ulmoides, 10 parts of wine-processed scutellaria baicalensis, 18 parts of prepared rehmannia root, 16 parts of teasel root, 12 parts of soil-fried bighead atractylodes rhizome, 10 parts of vinegar turtle shell, 28 parts of calcined oyster shell, 10 parts of Chinese date and 4 parts of pseudo-ginseng.
3. The pharmaceutical composition for treating postpartum diseases of women according to claim 1, which is prepared from the following traditional Chinese medicines in parts by weight: 15 parts of radix astragali preparata, 12 parts of codonopsis pilosula, 14 parts of charred eucommia ulmoides, 15 parts of wine-processed scutellaria baicalensis, 16 parts of prepared rehmannia root, 24 parts of teasel root, 8 parts of soil-fried bighead atractylodes rhizome, 8 parts of vinegar turtle shell, 22 parts of calcined oyster shell, 6 parts of Chinese date and 5 parts of pseudo-ginseng.
4. The pharmaceutical composition for treating postpartum diseases of women according to claim 1, which is prepared from the following traditional Chinese medicines in parts by weight: 15 parts of radix astragali preparata, 10 parts of codonopsis pilosula, 10 parts of charred eucommia ulmoides, 6 parts of wine-processed scutellaria baicalensis, 10 parts of prepared rehmannia root, 10 parts of teasel root, 8 parts of soil-fried bighead atractylodes rhizome, 12 parts of vinegar turtle shell, 20 parts of calcined oyster shell, 5 parts of Chinese date and 3 parts of pseudo-ginseng.
5. The pharmaceutical composition for treating postpartum diseases in women according to claim 1, wherein the pharmaceutical composition comprises: also comprises pharmaceutically acceptable auxiliary materials.
6. The pharmaceutical composition for treating postpartum diseases in women according to claim 1, wherein the pharmaceutical composition comprises: the pharmaceutical composition is any one of pharmaceutical oral preparations, and the oral preparation is granules, tablets, capsules, powder or pills.
7. A preparation method of a pharmaceutical composition for treating postpartum diseases of women is characterized by comprising the following steps:
s1, extracting the traditional Chinese medicine raw materials in parts by weight with water for 2-4 times according to the proportion, adding 10-15 times of water each time, and decocting for 0.5-2 hours;
s2, filtering and combining the filtrates obtained in the step S1, concentrating the filtrates to an extract with the relative density of 1.00-1.50, drying and crushing to obtain the tea extract.
CN202210587997.XA 2022-05-26 2022-05-26 A pharmaceutical composition for treating puerperal diseases, and its preparation method Active CN114869949B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210587997.XA CN114869949B (en) 2022-05-26 2022-05-26 A pharmaceutical composition for treating puerperal diseases, and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210587997.XA CN114869949B (en) 2022-05-26 2022-05-26 A pharmaceutical composition for treating puerperal diseases, and its preparation method

Publications (2)

Publication Number Publication Date
CN114869949A true CN114869949A (en) 2022-08-09
CN114869949B CN114869949B (en) 2023-06-20

Family

ID=82678076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210587997.XA Active CN114869949B (en) 2022-05-26 2022-05-26 A pharmaceutical composition for treating puerperal diseases, and its preparation method

Country Status (1)

Country Link
CN (1) CN114869949B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036158A (en) * 2022-09-09 2023-05-02 山西黄河中药有限公司 Pharmaceutical composition for treating gouty arthritis and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336997A (en) * 2008-08-11 2009-01-07 江苏济川制药有限公司 Medicine for hemorrhage after drug abortion
CN102240385A (en) * 2010-05-11 2011-11-16 西安兆兴制药有限公司 Traditional Chinese medicine dripping pill for treating woman postpartum disease and preparation method thereof
CN104147552A (en) * 2014-09-03 2014-11-19 河南科技大学第一附属医院 Traditional Chinese medicinal composition for treating blood stasis type postpartum abdominal pain and preparation method thereof
CN104274588A (en) * 2014-09-09 2015-01-14 宋永花 Traditional Chinese medicine for treating habitual abortion
CN104274589A (en) * 2014-09-12 2015-01-14 贺珍 Traditional Chinese medicine for treating postpartum anemic fainting
RU2015113319A (en) * 2012-09-13 2016-11-10 Джиангжонг Фармасьютикал Ко., Лтд. COMBINATION OF TRADITIONAL CHINESE MEDICINE FOR REGULATION OF IMMUNE FUNCTION AND METHOD FOR ITS PRODUCTION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336997A (en) * 2008-08-11 2009-01-07 江苏济川制药有限公司 Medicine for hemorrhage after drug abortion
CN102240385A (en) * 2010-05-11 2011-11-16 西安兆兴制药有限公司 Traditional Chinese medicine dripping pill for treating woman postpartum disease and preparation method thereof
RU2015113319A (en) * 2012-09-13 2016-11-10 Джиангжонг Фармасьютикал Ко., Лтд. COMBINATION OF TRADITIONAL CHINESE MEDICINE FOR REGULATION OF IMMUNE FUNCTION AND METHOD FOR ITS PRODUCTION
CN104147552A (en) * 2014-09-03 2014-11-19 河南科技大学第一附属医院 Traditional Chinese medicinal composition for treating blood stasis type postpartum abdominal pain and preparation method thereof
CN104274588A (en) * 2014-09-09 2015-01-14 宋永花 Traditional Chinese medicine for treating habitual abortion
CN104274589A (en) * 2014-09-12 2015-01-14 贺珍 Traditional Chinese medicine for treating postpartum anemic fainting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宋咏梅等: "《陈莲舫医著大成》", pages: 312 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036158A (en) * 2022-09-09 2023-05-02 山西黄河中药有限公司 Pharmaceutical composition for treating gouty arthritis and preparation method thereof
CN116036158B (en) * 2022-09-09 2023-10-13 山西黄河中药有限公司 Pharmaceutical composition for treating gouty arthritis and preparation method thereof

Also Published As

Publication number Publication date
CN114869949B (en) 2023-06-20

Similar Documents

Publication Publication Date Title
CN105920514A (en) Traditional Chinese medicinal composition for treating metabolic syndrome
CN102949630A (en) Traditional Chinese medicine composition for treating abdominal distension caused by lack of gastrointestinal motility
CN105362650A (en) Pharmaceutical composition for treating constipation and application method thereof
CN104225215A (en) Traditional Chinese medicine for treating insomnia
CN114869949A (en) A pharmaceutical composition for treating puerperal diseases, and its preparation method
CN102526345A (en) Chinese medicinal composition for treating hypertension
CN106421432A (en) Traditional Chinese medicine for treating aged body deficiency syndrome and delaying senescence
CN110339276A (en) Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof
CN103638456B (en) A kind of Chinese medicine for the treatment of liver cirrhosis and preparation method thereof
CN105311492A (en) Medicine for treating coronary atherosclerotic heart disease
CN109528968A (en) A kind of Chinese medicine composition and its preparation method and application for treating diabetes B
CN104042974A (en) Traditional Chinese medicament for treating diabetes mellitus
CN105362827A (en) Decoction capable of effectively treating anemia and preparation method thereof
CN105169189A (en) Medicament for treating hypothyroidism
CN104857370A (en) Traditional Chinese medicine composition for treating breast cancer
CN105267818A (en) Traditional Chinese medicine composition for treating epigastric pain and preparation method thereof
CN105106734A (en) Traditional Chinese medicine preparation for treating hyperemesis gravidarum
CN104840902A (en) Traditional Chinese medicine preparation for treating ovarian tumor
CN104922488B (en) A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application
CN108853340A (en) A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof
CN102362929B (en) Chinese medicinal composition and extract for treating cancer ischemia, and preparation method and formulation of Chinese medicinal extract
CN106421411A (en) Stomach tonifying functional beverage
CN106581272A (en) Traditional Chinese medicine composition for treating diabetes
CN105456954A (en) Traditional Chinese medicine composition for treating acne and preparation thereof
CN104623468A (en) Traditional Chinese medicine composition for treating postpartum hypogalactia of lying-in women and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant